Two-year results of the HORIZON study showed phacoemulsification combined with a Hydrus microstent significantly lowered IOP compared with phacoemulsification alone, according to a speaker here. In addition, patients who received the Hydrus were statistically more likely to remain medication-free.
“Hydrus-treated eyes had rapid visual recovery with 94% 20/40 or better after 1 week and 98% 20/40 or better after 1 month. The Hydrus study arm had fewer IOP spikes and required less subsequent glaucoma surgery compared to cataract surgery alone,” Thomas W. Samuelson, MD, said at the American Glaucoma Society annual meeting.
The HORIZON study included 556 patients with mild to moderate primary open-angle glaucoma randomized to cataract surgery alone or cataract surgery with the Hydrus (Ivantis).
At 24 months, 77.2% of patients in the Hydrus arm of the study experienced a 20% reduction in diurnal IOP compared with 57.8% of patients in the cataract surgery-alone arm.
“The Hydrus implantation significantly added to IOP reduction from phacoemulsification, and importantly the treatment effect is maintained throughout the 2-year study period, just as robust at 2 years as it is at 1 year,” Samuelson said.
